Angiochem

🗓 Founded 2003👥 10 employees💰 Last funded Jan 2006
Biotechnology🌐 angiochem.com
Website LinkedIn
Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in Angiochem?
Angiochem has 1 investors on record on gritt.io, 1 mid-stage.
When did Angiochem last raise funding?
The most recent investment in Angiochem recorded on gritt.io was in January 2006.
When was Angiochem founded?
Angiochem was founded in 2003.
What industry is Angiochem in?
Angiochem operates in Biotechnology. Find similar Biotechnology investors on gritt.io.